Genzyme Corp.

Cambridge-based biotechnology firm Genzyme announced the purchase of $23 million in stock from Alnylam Pharmaceuticals Inc.

Biotech giant Genzyme has bought a 12-percent stake in Cambridge-based Alnylam Pharmaceuticals in an investment valued at $700 million, Genzyme announced today.

Federal regulators formally rejected Genzyme's multiple sclerosis (MS) treatment over concerns about trial design and potentially serious side effects, the Cambridge-based drug maker said Monday.

Cambridge-based Genzyme has agreed to pay $22.28 million to resolve allegations brought by former employees that the biotechnology giant marketed an inappropriate use for a surgery medication, the U.S. Department of Justice said.

U.S. regulators said Friday that the risks from a multiple sclerosis (MS) drug developed by Cambridge-based Genzyme might outweigh its benefits and recommended against the drug's approval.

Biotech giant Genzyme will expand its Framingham campus with an $80-million processing facility that it says will “significantly” expand its purification capacity to support growth over the next few years, the Cambridge-based company announced today.

A flourishing life sciences industry has created a practical problem for companies that need to protect precious samples: how to store them.